Skip to main content
Clinical Trials/NCT07461103
NCT07461103
Completed
Phase 2

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

Alexandria University1 site in 1 country20 target enrollmentStarted: June 22, 2024Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
20
Locations
1
Primary Endpoint
Time to Complete Healing

Overview

Brief Summary

This study investigates the efficacy of topical insulin in promoting healing of pemphigus vulgaris erosions. Twenty patients with pemphigus vulgaris were enrolled, each contributing three comparable lesions randomly allocated to receive long-acting insulin (insulin glargine), short-acting insulin (regular insulin), or normal saline control. Treatments were applied topically twice daily for 14 days or until complete healing.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Confirmed diagnosis of pemphigus vulgaris by clinical and histopathological criteria
  • Presence of erosions and/or ulcers on skin and/or mucous membranes
  • At least three lesions of comparable location, size, depth, and healing stage

Exclusion Criteria

  • Lesions with clinical signs of secondary infection (purulence, surrounding erythema, fever)
  • Uncontrolled general condition significantly affecting wound healing (e.g., hypoalbuminemia)
  • Known allergy to insulin

Arms & Interventions

Long-acting insulin (LA)

Experimental

Lesions treated with topical insulin glargine (Lantus) 0.1 mL per 10 cm² twice daily

Intervention: insulin glargine (Drug)

Regular human insulin (SA)

Experimental

Lesions treated with topical regular insulin (Actrapid) 0.1 mL per 10 cm² twice daily

Intervention: human insulin (Drug)

control

Placebo Comparator

Lesions treated with topical 0.9% normal saline 0.1 mL per 10 cm² twice daily

Intervention: 0.9% Normal Saline (Drug)

Outcomes

Primary Outcomes

Time to Complete Healing

Time Frame: Up to 14 days

Number of days required for complete epithelialization of the lesion

Secondary Outcomes

  • Lesion Surface Area Reduction(Baseline, Day 7, Day 14)
  • Daily Healing Rate(14 days)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials